Breaking News

Cobra Biologics Appoints CSO

May 7, 2014

Smith to develop scientific excellence and enhance R&D platforms

Dr. Daniel C. Smith has been appointed chief scientific officer at Cobra Biologics, with responsibility for developing scientific excellence across the group and enhancing Cobra’s DNA, virus, microbial and mammalian proteins R&D platforms.
 
Dr. Smith joins the company from HealthTech & Medicines Knowledge Transfer Network (KTN), where he served as a Knowledge Transfer Manager on the bioProcessUK team, responsible for driving the innovation agenda for biologics bioprocessing in the UK. Previously, Dr. Smith held a variety of roles progressing from senior scientist to commercial scientific development manager, responsible for developing the strategy for customer’s projects, and maintaining scientific oversight of Cobra’s R&D projects.
 
Peter Coleman, chief executive officer at Cobra Biologics, said, “This is a significant appointment for Cobra and I am personally very pleased that Dan has decided to return to Cobra as our new CSO. He has a tremendous enthusiasm for science and its application in our industry and from working with him previously, I firmly believe he has experience and ability to further establish Cobra as a leading scientific organization.”
  • When Quality Meets Confidence

    When Quality Meets Confidence

    Dr. Fadia AlKhalil, Vice President of Global Business Development for Laboratory Services, SGS ||November 9, 2016
    A look at global account management for R&D outsourcing

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus